Progression of age-related macular degeneration: Prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers

Archives of Ophthalmology

Volumn 123, Issue 6, 2005, Pages 774-782

  Seddon, Johanna M ^a,b,c,d   George, Sarah ^a   Rosner, Bernard ^b,c   Rifai, Nader ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; LIPOPROTEIN A; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EYE; FEMALE; FOLLOW UP; HUMAN; HYPOTHESIS; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OPHTHALMOSCOPY; OUTCOMES RESEARCH; PHOTOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SMOKING; VISUAL ACUITY; BLOOD; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RETINA MACULA DEGENERATION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIPOPROTEIN(A); MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 20644467790     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.123.6.774     Document Type: Article

References (51)

1. National Advisory Eye Council. Vision Research - A National Plan: 1999-2003, Vol. 1: A Report of the National Advisory Eye Council. Bethesda, Md: National Institutes of Health; 1999. NIH publication 98-4120.
2. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA. 1996;276:1141-1146.
3. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108:697-704.
4. Seddon JM, Ajani UA, Sperduto RD, et al; Eye Disease Case-Control Study Group. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA. 1994;272:1413-1420.
5. Seddon JM, Rosner B, Sperduto RD, et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol. 2001;119:1191-1199.
6. Cho E, Hung S, Willett W, et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr. 2001;73:209-218.
7. Age-Related Eye Disease Study Research Group. A randomized, placebocontrolled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Arch Ophthalmol. 2001;119:1417-1436.
8. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol. 2003;121:1728-1737.
9. VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BE, Brady WE, Palta M. Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol. 1998;148:204-214.
10. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: association with body mass index, waist circumference and waist-hip ratio. Arch Ophthalmol. 2003;121:785-792.
11. Age-Related Eye Disease Study Research Group. Risk factors associated with age related macular degeneration: a case-control study in the Age-Related Eye Disease Study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107:2224-2232.
12. Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 1992;110:1701-1708.
13. Snow K, Seddon J. Do age related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol. 1999;6:125-143.
14. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA. 2004;291:704-710.
15. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537-547.
16. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol. 1998;31:1460-1465.
17. Rifai N, Joubran R, Yu H, Asmi M, Jouma M. Inflammatory markers in men with angiographically documented coronary heart disease. Clin Chem. 1999;45:1967-1973.
18. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
19. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor- α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-2153.
20. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
21. Porsch-Oezcueruemez M, Kunz D, Kloer HU, Luley C. Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease. J Am Coll Cardiol. 1999;34:1995-2001.
22. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selection in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96:4219-4225.
23. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation. 2002;106:820-825.
24. Blankenberg S, Rupprecht HJ, Bickel C. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104:1336.
25. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18:842-851.
26. De Simone M, Verrotti A, Cappa M, et al. Lipoprotein (a) in childhood: correlations with family history of cardiovascular disease. J Endocrinol Invest. 2003;26:414-419.
27. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23 suppl 1):III2-III7.
28. Williams K, Sniderman AD, Naveed S, D'Agostino R Jr, Wagenknecht LE, Haffner SM. Comparison of the associations of apoliopoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003;108:2312-2316.
29. Pavan PR, Margo CE. Submacular neovascular membrane and focal granulomatous inflammation. Ophthalmology. 1996;103:586-589.
30. Lindsberg PJ, Grau AJ. Inflammation and inflections as risk factors for ischemic stroke. Stroke. 2003;34:2518-2532.
31. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-432.
32. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry. 1994;151:1105-1113.
33. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 2000;70:441-449.
34. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835-846.
35. Hageman GS, Luthert PJ, Chong NHV, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-723.
36. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887-896.
37. Anderson DH, Mullins RF, Hageman GS, Johnson LV. Perspective: a role of local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
38. Ajani U, Willett W, Seddon J. Reproducibility of a food frequency questionnaire for use in ocular research. Invest Ophthalmol Vis Sci. 1994;35:2725-2733.
39. Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91-96.
40. Seddon JM, Santangelo SL, Book K, Chong S, Cote J. A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions. Am J Hum Genet. 2003;73:780-790.
41. Seddon JM, Samelson LJ, Page WF, Neale MC. Twin study of macular degeneration: methodology and application to genetic epidemiologic studies [ARVO abstract]. Invest Ophthalmol Vis Sci. 1997;38:S676. Abstract. 3172.
42. Adelman R, Sharma S, Seddon JM. Evaluation of the Clinical Age-Related Maculopathy Staging System (CARMS). Paper presented at: Annual Meeting of the American Academy of Ophthalmology; October 22, 2000; Dallas, Tex.
43. Seddon JM, Cote J, Page WF, Aggen SH, Neale MC. The US twin study of agerelated macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol. 2005;123:321-327.
44. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem. 2000;46:1956-1967.
45. Sunness JS, Gonzalez-Baron J, Bressler NM, Hawkins B, Applegate CA. The development of choroidal neovascularization in eyes with geographic atrophy form of age-related macular degeneration. Ophthalmology. 1999;106:910-919.
46. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20:385-414.
47. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
48. Hall N, Martyn C. Could statins prevent age-related macular degeneration? Expert Opin Pharmacother. 2002;3:803-807.
49. Klein R, Klein BE. Do statins prevent age-related macular degeneration? Am J Ophthalmol. 2004;137:747-749.
50. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 2003;87:462-468.
51. Age-Related Eye Disease Study Research Group. Potential public health impact of age-related eye disease study results: AREDS report No. 11. Arch Ophthalmol. 2003;121:1621-1624.